1) 日本婦人科腫瘍学会 : 子宮体癌治療ガイドライン,2009年度版.金原出版,2009
2) NCCN Clinical Practice Guidelines in Oncology : Uterine Neoplasms, v.1.2010. http://www.nccn.org/professionals/physician_gls/PDF/uterine.pdf
3) Creutzberg CL, van Putten WLJ, Koper PC, et al : Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma : multicentre randomised trial. PORTEC Study Group. Post Operative Radiation Therapy in Endometrial Carcinoma. Lancet 355 : 1404─1411, 2000
4) Creutzberg CL, van Putten WL, Koper PC, et al : The morbidity of treatment for patients with Stage I endometrial cancer : results from a randomized trial. Int J Radiat Oncol Phys 51 : 1246─1255, 2001
5) Nout RA, SmitVT, Putter H, et al : Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk(PORTEC-2): an open-label, non-inferiority, randomised trial. Lancet 375(9717): 816─823, 2010
6) Keys HM, Roberts JA, Brunetto VL, et al : A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma : a Gynecologic Oncology Group Study. Gynecol Oncol 92 : 744─751, 2004
7) Blake P, Swart AM, Orton J, et al : Adjuvant external beam radiotherapy in the treatment of endometrial cancer(MRC ASTEC and NCIC CTG EN.5 randomised trials): pooled trial results, systematic review, and meta-analysis. Lancet 373 : 137─146, 2009
8) Kong A, Simera I, Collingwood M, et al : Adjuvant radiotherapy for stage I endometrial cancer : systematic review and meta-analysis. Ann Oncol 18 : 1595─1604, 2007
9) Beriwal S, Jain SK, Heron DE, et al : Clinical outcome with adjuvant treatment of endometrial carcinoma using intensity-modulated radiation therapy. Gynecol Oncol 102 : 195─199, 2006
10) Thigpen JT, Buchsbaum HJ, Mangan C, et al : Phase II trial of adriamycin in the treatment of advanced or recurrent endometrial carcinoma : a Gynecologic Oncology Group Study. Cancer Treat Rep 63 : 21─27, 1979
11) Calero F, Asins-Codoñer E, Jimeno J, et al : Epirubicin in advanced endometrial adenocarcinoma : a phase II study of the grupo ginecologico español para el tratamiento oncologico(GGETO).Eur J Cancer 27 : 864─866, 1991
12) Thigpen JT, Blessing JA, Homesley H, et al : Phase II trial of cisplatin as first─line chemotherapy in patients with advanced or recurrent endometrial carcinoma : a Gynecologic Oncology Group Study. Gynecol Oncol 33 : 68─70, 1989
13) Long HJ, Pfeifle DM, Wieand HS, et al : Phase II evaluation of carboplatin in advanced endometrial carcinoma. J Natl Cancer Inst 80 : 276─278, 1988
14) Wadler S, Levy DE, Lincoln ST, et al : Topotecan is an active agent in the first-line treatment of metastatic or recurrent endometrial carcinoma : Eastern Cooperative Oncology Group Study E3E93. J Clin Oncol 21 : 2110─2114, 2003
15) Hirai Y, Hasumi K, Onose R, et al : Phase II trial of 3-h infusion of paclitaxel in patients with adenocarcinoma of endometrium : Japanese Multicenter Study Group. Gynecol Oncol 94 : 471─476, 2004
16) Katsumata N, Noda K, Nozawa S, et al : Phase II trial of docetaxel in advanced or metastatic endometrial cancer : a Japanese Cooperative Study. Br J Cancer 93 : 999─1004, 2005
17) Thigpen JT, Blessing JA, DiSaia PJ, et al : A randomized comparison of doxorubicin alone versus doxorubicin plus cyclophosphamide in the management of advanced or recurrent endometrial carcinoma : a Gynecologic Oncology Group Study. J Clin Oncol 12 : 1408─1414, 1994
18) Thigpen JT, Brady MF, Homesley HD, et al : Phase III trial of doxorubicin with or without cisplatin in advanced endometrial carcinoma : a Gynecologic Oncology Group Study. J Clin Oncol 22 : 3902─3908, 2004
19) Aapro MS, Wijk FH, Bolis G, et al : Doxorubicin versus doxorubicin and cisplatin in endometrial carcinoma : Definitive Results of a Randomised Study(55872)by the EORTC Gynecologic Cancer Group. Ann Oncol 14 : 441─448, 2003
20) Fleming GF, Filiaci VL, Bentley RC, et al : Phase III randomized trial of doxorubicin+cisplatin versus doxorubicin+24─h paclitaxel+filgrastim in endometrial carcinoma : a Gynecologic Oncology Group Study. Ann Oncol 15 : 1173─1178, 2004
21) Fleming GF, Brunetto VL, Cella D, et al : Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma : a Gynecologic Oncology Group Study. J Clin Oncol 22 : 2159─2166, 2004
22) Randall ME, Filiaci VL, Muss H, et al : Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma : a Gynecologic Oncology Group Study. J Clin Oncol 24 : 36─44, 2006
23) Susumu N, Sagae S, Udagawa Y, et al : Randomized phase III trial of pelvic radiotherapy versus cisplatin-based combined chemotherapy in patients with intermediate- and high-risk endometrial cancer : A Japanese Gynecologic Oncology Group Study. Gynecol Oncol 108 : 226─233, 2008
24) Homesley HD, Filiaci V, Gibbons SK, et al : A randomized phase III trial in advanced endometrial carcinoma of surgery and volume directed radiation followed by cisplatin and doxorubicin with or without paclitaxel : A Gynecologic Oncology Group study. Gynecol Oncol 112 : 543─552, 2009
25) Hiura M, Nogawa T, Matsumoto T, et al : Long-term survival in patients with para-aortic lymph node metastasis with systematic retroperitoneal lymphadenectomy followed by adjuvant chemotherapy in endometrial carcinoma. Int J Gynecol Cancer 20 : 1000─1005, 2010
26) Sovak MA, Dupont J, Hensley ML, et al : Paclitaxel and carboplatin in the treatment of advanced or recurrent endometrial cancer : a large retrospective study. Int J Gynecol Cancer 17 : 197─203, 2007
27) Secord AA, Havrilesky LJ, Camey ME, et al : Weekly low-dose paclitaxel and carboplatin in the treatment of advanced or recurrent cervical and endometrial cancer. Int J Clin Oncol 12 : 31─36, 2007